Public-registry trials using Dostarlimab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer | GlaxoSmithKline | Neoplasms, Rectal | PHASE3 | 0 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
